This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...

Dukhi Hong, 84, has confounded medics to far exceed their six month prognosis following her diagnosis with small cell lung ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The programme aims to enhance access to targeted cancer therapies by identifying actionable genetic mutations in lung cancer patients ...

Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...

A study found a "significant" link between the frequency of chest X-ray referrals and improved survival rates for lung cancer ...

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in ...